Generic placeholder image

Current Pharmacogenomics and Personalized Medicine

Editor-in-Chief

ISSN (Print): 1875-6921
ISSN (Online): 1875-6913

Review Article

Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors

Author(s): Wei-Hua Shao, Lei-Yun Wang and Ji-Ye Yin*

Volume 16, Issue 2, 2018

Page: [108 - 117] Pages: 10

DOI: 10.2174/1875692116666180821152601

Abstract

Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.

Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.

Next »
Graphical Abstract

© 2024 Bentham Science Publishers | Privacy Policy